Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash & Equivalents (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Cash & Equivalents for 13 consecutive years, with $91.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 87.5% year-over-year to $91.9 million, compared with a TTM value of $91.9 million through Sep 2025, up 87.5%, and an annual FY2024 reading of $69.2 million, up 17.61% over the prior year.
  • Cash & Equivalents was $91.9 million for Q3 2025 at Tandem Diabetes Care, up from $64.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $172.5 million in Q4 2022 and bottomed at $47.7 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $91.5 million, with a median of $91.9 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents soared 142.36% in 2022, then tumbled 65.88% in 2023.
  • Year by year, Cash & Equivalents stood at $71.2 million in 2021, then skyrocketed by 142.36% to $172.5 million in 2022, then crashed by 65.88% to $58.9 million in 2023, then grew by 17.61% to $69.2 million in 2024, then skyrocketed by 32.81% to $91.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for TNDM at $91.9 million in Q3 2025, $64.1 million in Q2 2025, and $53.6 million in Q1 2025.